Macrolides for macrophages in chronic obstructive pulmonary disease

Respirology

Volumn 17, Issue 5, 2012, Pages 739-740

  Hansbro, Philip M ^a   Jarnicki, Andrew G ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

chronic obstructive pulmonary disease; exacerbations; macrolides; macrophage; phagocytosis

Indexed keywords

AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ELASTASE; ERYTHROMYCIN; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; METHYLXANTHINE DERIVATIVE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY OBSTRUCTION; BACTERIAL INFECTION; BRONCHIOLITIS OBLITERANS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DETERIORATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EDITORIAL; HUMAN; IMMUNOMODULATION; LONG TERM CARE; LUNG ALVEOLUS MACROPHAGE; LUNG TRANSPLANTATION; PERSONALIZED MEDICINE; PHAGOCYTOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SPUTUM LEVEL; VIRUS INFECTION;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; ESCHERICHIA COLI; FEMALE; HUMANS; MACROPHAGES; MACROPHAGES, ALVEOLAR; MALE; PHAGOCYTOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84862994387     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02186.x     Document Type: Editorial

References (31)

1. Keely S, Talley NJ, Hansbro PM,. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol. 2012; 5: 7-18.
2. Wedzicha JA, Donaldson GC,. Exacerbations of chronic obstructive pulmonary disease. Respir. Care 2003; 48 (12): 1204-13.
3. Patel IS, Seemungal TAR, Wilks M, et al,. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759-64. (Pubitemid 34984972)
4. Yasothan U, Kar S,. Therapies for COPD. Nat. Rev. Drug Discov. 2008; 7: 285-6.
5. Jones R, Ostrem A,. Optimising pharmacological maintenance treatment for chronic obstructive pulmonary disease in primary care. Prim. Care Respir. J. 2011; 20: 33-45.
6. Yang IA, Fong KM, Sim EHA, et al,. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2007; (2): CD002991.
7. Barnes PJ,. Alveolar macrophages as orchestrators of COPD. COPD 2004; 1: 59-70.
8. Prieto A, Reyes E, Bernstein ED, et al,. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferõn). Am. J. Respir. Crit. Care Med. 2001; 163: 1578-83. (Pubitemid 32578759)
9. Berenson CS, Garlipp MA, Grove LJ, et al,. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J. Infect. Dis. 2006; 194: 1375-84. (Pubitemid 44706505)
10. Hodge S, Hodge G, Ahern J, et al,. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2007; 37: 748-55. (Pubitemid 350211645)
11. Taylor AE, Finney-Hayward TK, Quint JK, et al,. Defective macrophage phagocytosis of bacteria in COPD. Eur. Respir. J. 2010; 35: 1039-47.
12. Karavitis J, Kovacs EJ,. Macrophage phagocytosis: effects of environmental pollutants, alcohol, cigarette smoke, and other external factors. J. Leukoc. Biol. 2011; 90: 1065-78.
13. Hodge S, Hodge G, Scicchitano R, et al,. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol. Cell Biol. 2003; 81: 289-96. (Pubitemid 36904336)
14. Hodge S, Hodge G, Jersmann H, et al,. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 178: 139-48. (Pubitemid 351957772)
15. Hodge S, Matthews G, Mukaro V, et al,. Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine. Am. J. Respir. Cell Mol. Biol. 2011; 44: 673-81.
16. Hodge S, Reynolds PN,. Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in COPD subjects. Respirology 2012; 17: 803-8.
17. Martinez FJ, Curtis JL, Albert R,. Role of macrolide therapy in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2008; 3: 331-50.
18. Villagrasa V, Berto L, Cortijo J, et al,. Effects of erythromycin on chemoattractant-activated human polymorphonuclear leukocytes. Gen. Pharmacol. 1997; 29: 605-9. (Pubitemid 27421428)
19. Kanai K-I, Asano K, Hisamitsu T, et al,. Suppression of matrix metalloproteinase-9 production from neutrophils by a macrolide antibiotic, roxithromycin, in vitro. Mediators Inflamm. 2004; 13: 313-9. (Pubitemid 40018364)
20. Verleden SE, Vandooren J, Vos R, et al,. Azithromycin decreases MMP-9 expression in the airways of lung transplant recipients. Transpl. Immunol. 2011; 25: 159-62.
21. Asgrimsson V, Gudjonsson T, Gudmundsson GH, et al,. Novel effects of azithromycin on tight junction proteins in human airway epithelia. Antimicrob. Agents Chemother. 2006; 50: 1805-12.
22. Yang M, Dong BR, Lu J, et al,. Macrolides for diffuse panbronchiolitis. Cochrane Database Syst. Rev. 2010; (12): CD007716.
23. Southern KW, Barker PM, Solis-Moya A, et al,. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 2011; (12): CD002203.
24. Vanaudenaerde BM, Meyts I, Vos R, et al,. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur. Respir. J. 2008; 32: 832-42.
25. Cazzola M, Blasi F, Terzano C, et al,. Delivering antibacterials to the lungs: considerations for optimizing outcomes. Am. J. Respir. Med. 2002; 1: 261-72. (Pubitemid 37038945)
26. McLean-Tooke A, Aldridge C, Stroud C, et al,. Practical management of antibiotic allergy in adults. J. Clin. Path. 2011; 64: 192-9.
27. Leclercq R, Courvalin P,. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob. Agents Chemother. 1991; 35: 1267-72.
28. Gomez J, Banos V, Simarro E, et al,. Prospective, comparative study (1994-1998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD. Rev. Esp. Quimioter. 2000; 13: 379-83. (Pubitemid 32125753)
29. Albert RK, Connett J, Bailey WC, et al,. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 365: 689-98.
30. Molinari G, Guzmán CA, Pesce A, et al,. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J. Antimicrob. Chemother. 1993; 31: 681-8. (Pubitemid 23193729)
31. Sethi S,. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? Proc. Am. Thorac. Soc. 2004; 1: 109-14.